INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
14/04/2026
Voltar para busca
Dado oficial do USPTO
QUANTINOVA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
15/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
16/10/2013
Data de registro
16/09/2014
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/02/2025
Última transação
15/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Hilden, DE
Examinador
ELTON, DAVID JONATHAN
Localização atual
Historical data usage
Titulares e representantes
Titulares
Qiagen GmbH
Qiagen GmbH
Representantes
VICTORIA FRIEDMAN Dennemeyer & Associates, LLC
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemical and biotechnological products for industrial and scientific purposesreagents and solvents for scientific and research use in the nature of sample preparation and for conducting markingseparatingisolatingpurifyingduplicating and analysis methods for biopolymersnucleic acids and enzymes; polymerase chain reaction (PCR) reagents for industrial and scientific purposes; chemical reagents for amplification and detection of nucleic acids for industrial and scientific purposes; chemical reagents for real-time and quantitative amplification and detection of nucleic acids for industrial and scientific purposes; chemical reagents for complementary DNA (cDNA) synthesis for scientific research purposes; chemical reagents for amplification and detection of ribonucleic acid (RNA) for scientific research purposes; chemical reagents for conversion of RNA into cDNA for scientific research purposes; test kits comprising chemical preparations for industrial and scientific purposeskits comprising reagents and solvents for scientific research use for conducting markingseparatingisolatingpurifyingduplicating and analysis methods for biopolymersnucleic acidskits comprising polymerase chain reaction (PCR) reagents for industrial and scientific research purposes; chemical reagents for amplification and detection of nucleic acids for industrial and scientific purposes; kits comprising chemical reagents for real-time and quantitative amplification and detection of nucleic acids for industrial and scientific purposes; kits comprising chemical reagents for complementary DNA (cDNA) synthesis for scientific research purposes; kits comprising chemical reagents for amplification and detection of ribonucleic acid (RNA) for scientific research purposes; kits comprising chemical reagents for conversion of RNA into cDNA for scientific research purposes
Classe 5
Diagnostic reagents for medical and veterinary medical purposesmedical diagnostic reagents for conducting markingseparatingisolatingpurifyingduplicating and analysis methods for biopolymersnucleic acids and enzymes; polymerase chain reaction (PCR) reagents for medical and veterinary medical purposes; reagents for amplification and detection of nucleic acids for medical and veterinary medical purposes; reagents for real-time and quantitative amplification and detection of nucleic acids for medical and veterinary medical purposes; reagents for complementary DNA (cDNA) synthesis for medical and veterinary medical purposes; kits comprising diagnostic preparations for medical and veterinary medical diagnostic purposeskits comprising medical diagnostic reagents for conducting markingseparatingisolatingpurifyingduplicating and analysis methods for biopolymersnucleic acids; kits comprising polymerase chain reaction (PCR) reagents for medical and veterinary medical purposes; kits comprising reagents for amplification and detection of nucleic acids for medical and veterinary medical purposes; kits comprising reagents for real-time and quantitative amplification and detection of nucleic acids for medical and veterinary medical purposes; kits comprising reagents for complementary DNA (cDNA) synthesis for medical and veterinary medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
19/10/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
19/02/2025
71AG
REGISTERED-SEC.71 ACCEPTED
19/02/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
18/02/2025
ES71
TEAS SECTION 71 RECEIVED
30/08/2024
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
16/09/2023
RNWL
INTERNATIONAL REGISTRATION RENEWED
31/08/2023
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
03/11/2021
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
20/09/2021
INPC
INVALIDATION PROCESSED
20/09/2021
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
05/09/2021
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
05/01/2021
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
05/01/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/12/2020
ES75
TEAS SECTION 71 & 15 RECEIVED
21/08/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/10/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/03/2015
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/02/2015
FIMP
FINAL DISPOSITION PROCESSED
24/02/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
16/12/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
16/09/2014
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/08/2014
PUBO
PUBLISHED FOR OPPOSITION
01/07/2014
NPUB
NOTICE OF PUBLICATION
11/06/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
27/05/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/05/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/05/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/05/2014
ALIE
ASSIGNED TO LIE
14/05/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/05/2014
RFNT
REFUSAL PROCESSED BY IB
18/04/2014
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
31/03/2014
RFRR
REFUSAL PROCESSED BY MPU
31/03/2014
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/03/2014
CNRT
NON-FINAL ACTION WRITTEN
29/03/2014
MAFR
APPLICATION FILING RECEIPT MAILED
25/03/2014
DOCK
ASSIGNED TO EXAMINER
21/03/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/03/2014
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
20/03/2014
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace QUANTINOVA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.